List of Excipients in Branded Drug NAPROSYN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmaceutical Associates Inc	NAPROSYN	naproxen	0121-0899	FD&C YELLOW NO. 6
Pharmaceutical Associates Inc	NAPROSYN	naproxen	0121-0899	FUMARIC ACID
Pharmaceutical Associates Inc	NAPROSYN	naproxen	0121-0899	MAGNESIUM ALUMINUM SILICATE
Pharmaceutical Associates Inc	NAPROSYN	naproxen	0121-0899	METHYLPARABEN

Naprosyn Excipient Strategy and Commercial Opportunities for Naproxen Products

Last updated: August 17, 2026

Naprosyn is a mature naproxen brand with limited product-level exclusivity and extensive generic competition. The commercial opportunity is not in replicating the immediate-release tablet. It is in differentiated excipient systems that improve dissolution, gastrointestinal tolerability, adherence, pediatric usability, or dose convenience while supporting a defensible regulatory and intellectual-property position.

What is Naprosyn and which active ingredient does it contain?

Naprosyn contains naproxen, a nonsteroidal anti-inflammatory drug used for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, tendinitis, bursitis, acute gout, and dysmenorrhea. Naproxen is the active ingredient in the conventional Naprosyn tablet, while naproxen sodium is used in products such as Anaprox and several over-the-counter products.

Naproxen is a weak acid with low aqueous solubility in its unionized form. Naproxen sodium has materially higher water solubility and can support faster dissolution and earlier absorption. The distinction creates separate formulation strategies:

Product type	Active form	Primary formulation issue	Commercial implication
Naprosyn immediate-release tablet	Naproxen	Slow dissolution in acidic conditions	Low-cost generic market
Naprosyn delayed-release tablet	Naproxen	Controlled release until intestinal exposure	Differentiation through coating and release profile
Naproxen sodium tablet	Naproxen sodium	Rapid dissolution and onset	Competes in pain and OTC categories
Suspension or liquid	Naproxen or naproxen sodium	Solubility, taste, sedimentation	Pediatric and swallowing-impaired patients
Topical or local delivery	Naproxen	Skin penetration and dose delivery	New dosage-form opportunity, but higher development risk

The FDA approved Naprosyn in the 1970s. Its core composition and basic product claims are legacy assets. Current commercial value depends on manufacturing scale, brand recognition, supply reliability, and formulation differentiation rather than basic active-ingredient exclusivity.

What excipients are used in Naprosyn tablets?

Naprosyn tablet excipients vary by strength, market, dosage form, and manufacturing revision. FDA labeling identifies inactive ingredients for the relevant approved product, and those records should control any product-specific composition analysis.[1]

Typical excipient functions in immediate-release naproxen tablets include:

Excipient function	Representative excipient classes	Role in naproxen formulation
Dilution and tablet mass	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Supports dose uniformity and compression
Binding	Povidone, hypromellose, pregelatinized starch	Improves granule and tablet strength
Disintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate	Accelerates tablet breakup
Lubrication	Magnesium stearate, stearic acid	Reduces tooling friction
Glidancy	Colloidal silicon dioxide, talc	Improves powder flow
Coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Protects the tablet and supports identification
Delayed release	Methacrylic acid copolymers, plasticizers, anti-tacking agents	Controls release above a target pH

The formulation objective is not simply to maximize disintegration. Excessive lubrication, hydrophobic excipients, or dense granulation can slow dissolution of naproxen. A formulation with rapid tablet breakup can still exhibit inadequate drug release if the active remains poorly wetted or precipitates after pH change.

How should companies design an excipient strategy for naproxen?

A commercially viable strategy should begin with the target product profile, not with a preferred excipient. The highest-value variables are onset, duration, gastric exposure, dose flexibility, patient acceptability, and manufacturing cost.

Immediate-release naproxen

For a standard tablet, the strongest development route is a robust, low-cost composition with rapid disintegration and reproducible dissolution. Relevant approaches include:

• Hydrophilic fillers to improve wetting.
• Superdisintegrants with controlled concentration to avoid excessive tablet swelling.
• Wet granulation or dry granulation selected according to flow and content-uniformity requirements.
• Low-level surfactants where justified by dissolution data.
• Film coating that does not materially delay release.
• Direct-compression platforms that reduce process steps and cost.

The commercial ceiling is low because generic manufacturers already supply immediate-release naproxen at low prices. A new tablet needs a specific advantage, such as smaller size, lower tablet burden, improved stability in humid climates, or compatibility with a branded adherence program.

Delayed-release and enteric-coated naproxen

Delayed-release products can use pH-dependent polymers to reduce release in the stomach and promote release in the intestine. The coating system may include an enteric polymer, plasticizer, anti-tacking agent, pore former, and subcoat.

This strategy can support a differentiated product, but the clinical proposition must be narrow. Enteric coating does not eliminate systemic NSAID toxicity, cardiovascular risk, renal risk, or all gastrointestinal injury. A label claim implying broad gastrointestinal protection would face substantial clinical and regulatory scrutiny.

The formulation opportunity is strongest where the product can demonstrate:

• Reproducible resistance to acidic media.
• Prompt release at intestinal pH.
• Stable dissolution after long-term storage.
• Reduced gastric dissolution or local irritation.
• Acceptable bioequivalence or clinically justified exposure.

The development burden is higher than for an immediate-release tablet because coating uniformity, dissolution method design, batch scale-up, and food effects become central risks.

Naproxen sodium and rapid-onset products

Naproxen sodium is the most direct route to faster dissolution. Excipient selection should preserve the sodium salt, prevent conversion to poorly soluble naproxen during manufacture, and maintain chemical stability under humidity exposure.

Potential platforms include:

• Effervescent powders or granules.
• Rapidly disintegrating tablets.
• Orally disintegrating tablets.
• Liquid-filled hard capsules.
• Softgels.
• Sachets or unit-dose powders.

Surfactants, alkalizing agents, buffering systems, and moisture barriers may improve performance. These systems also increase packaging and stability requirements. Moisture-sensitive effervescent products may require high-barrier foil, desiccants, or nitrogen-controlled packaging.

What formulation patents could protect a new Naprosyn product?

The basic naproxen molecule and conventional Naprosyn tablet are mature technologies. New patent value would likely come from a narrow formulation or manufacturing claim, such as:

1. A defined naproxen-to-excipient ratio that produces a specified dissolution profile.
2. A multilayer tablet separating naproxen from an alkalizing or reactive excipient.
3. A controlled-release matrix with a defined polymer combination.
4. A taste-masked liquid or orally disintegrating formulation.
5. A particle-engineered naproxen or naproxen sodium composition.
6. A high-load tablet with improved compressibility and reduced tablet size.
7. A moisture-stable granule or unit-dose package.
8. A manufacturing process that controls polymorph, particle size, or residual solvent.
9. A pediatric formulation with dose flexibility and acceptable palatability.
10. A combination product with gastroprotective therapy, subject to clinical and regulatory requirements.

Composition claims are usually stronger when the formulation has a measurable technical effect, such as improved dissolution, reduced variability, enhanced stability, or a clinically relevant exposure profile. Broad claims covering ordinary binders, disintegrants, and lubricants are vulnerable to enablement, written-description, obviousness, and prior-art challenges.

When does Naprosyn lose exclusivity and what is the Orange Book status?

Naprosyn’s core small-molecule exclusivity expired decades ago. Generic naproxen and naproxen sodium products are widely marketed in the United States and internationally. The relevant commercial question is therefore not whether generic entry is possible. It is whether a new product can obtain separate regulatory exclusivity or patent protection for a differentiated dosage form.

The FDA Orange Book identifies approved drug products, therapeutic-equivalence evaluations, patent listings, and regulatory exclusivity for eligible products.[2] A current project should review the live Orange Book record for the specific Naprosyn NDA and any related delayed-release or combination product. Legacy Naprosyn patents should not be treated as current barriers without confirming their listing status, expiration, pediatric adjustments, and any applicable terminal disclaimers.

Potential protection for a new product could arise through:

• New formulation patents.
• New method-of-use patents.
• Three-year FDA exclusivity for a new clinical investigation supporting approval of a change, where statutory requirements are met.
• Five-year new chemical entity exclusivity, which is generally unavailable for a conventional naproxen reformulation.
• Orphan-drug exclusivity, unlikely for ordinary Naprosyn indications.
• Pediatric exclusivity, if an eligible written request is completed and statutory conditions are met.

What generic entry risks exist for a new naproxen formulation?

The risk profile depends on the regulatory pathway.

Product strategy	Likely pathway	Main competitor risk
Same immediate-release tablet	ANDA under Section 505(j)	Direct generic substitution and price erosion
Same delayed-release product	ANDA if a suitable reference product exists	Paragraph IV challenge and therapeutic-equivalence competition
New release profile or dosage form	505(b)(2) NDA	Follow-on 505(b)(2) applications and formulation patents
Pediatric liquid	505(b)(2) or ANDA, depending on reference	Competing liquids and pharmacy compounding
OTC naproxen sodium product	OTC monograph or NDA pathway	Private-label and retailer-owned brands
Combination with gastroprotection	505(b)(2) or full NDA	Clinical differentiation and combination-product competition

An ANDA applicant may file a Paragraph IV certification against listed patents, asserting that a patent is invalid, unenforceable, or not infringed. A patent-holder lawsuit can trigger a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions.[3]

A 505(b)(2) product may avoid direct duplication of the reference formulation, but it remains exposed to patent litigation, clinical bridging requirements, and competing reformulations. Patent strategy should focus on claims that a competitor cannot easily design around, while preserving freedom to operate for excipient suppliers, coating systems, and contract manufacturers.

Which excipient opportunities have the strongest commercial potential?

Pediatric and swallowing-impaired formulations

A palatable liquid, mini-tablet, dispersible tablet, or granule is a realistic opportunity. Naproxen’s taste and low water solubility make flavor masking and suspension control important. Commercial success would depend on:

• Acceptable taste at therapeutic concentrations.
• Uniform dosing after shaking.
• Low sedimentation and easy redispersion.
• Preservative and microbiological control.
• Dosing syringes or other administration devices.
• Flexible dose increments.

A pediatric indication may support regulatory differentiation, but it would require appropriate clinical and safety development. A product marketed only for adult pain relief would have a smaller exclusivity opportunity.

Smaller tablets and adherence-oriented products

Naproxen doses can require relatively large tablets. High-load formulations using optimized granulation, co-processed excipients, or particle engineering may reduce tablet size. This is commercially attractive for chronic arthritis patients and older adults who take multiple medicines.

The patent position should link the excipient system to a defined tablet-size reduction, compression profile, dissolution result, or stability improvement.

Rapid-onset naproxen sodium

Rapid-dissolution sachets, effervescent systems, orally disintegrating tablets, and softgels can compete in the self-care pain market. The opportunity is strongest where the product has a clear consumer benefit and packaging can support moisture protection.

The principal risks are limited clinical differentiation, crowded OTC competition, dose-combination restrictions, and retailer pricing pressure.

Modified-release products

Extended-release naproxen may reduce dosing frequency, but the commercial case is more difficult. NSAID exposure is dose- and duration-sensitive, and a prolonged-release product may create safety concerns if adverse effects occur. A sustained-release system must demonstrate reliable exposure without an unfavorable peak-trough profile.

Fixed-dose gastroprotective combinations

Combining naproxen with a proton-pump inhibitor can improve adherence to gastroprotection in selected patients. The opportunity is clinically meaningful but requires evidence supporting the combination, appropriate patient selection, and careful labeling. Excipients alone will not establish a gastroprotective claim.

How does Naprosyn compare with competing naproxen products?

Product category	Competitive position	Excipient-led opportunity
Generic naproxen tablet	Lowest-cost benchmark	Limited unless manufacturing cost or usability improves
Naproxen sodium OTC tablet	Faster dissolution and broad consumer awareness	Rapid-release and consumer-friendly formats
Delayed-release naproxen	Smaller market and more technical complexity	Enteric coating, dissolution control, adherence
Naproxen suspension	Pediatric and swallowing-use case	Taste masking, suspension stability, dosing accuracy
Naproxen gastroprotective combination	Higher clinical differentiation	Combination compliance and risk-management value
Topical naproxen	Potentially lower systemic exposure	Permeation enhancers, gels, patches, local delivery

Ibuprofen, diclofenac, celecoxib, and other NSAIDs create therapeutic competition. Naproxen has a recognized place in pain and inflammatory disease, but an excipient strategy must compete against both generic price and alternative active ingredients.

What manufacturing and geographic barriers affect the opportunity?

The main manufacturing barriers are not raw-material scarcity. They are process control and product consistency:

• Naproxen particle-size distribution.
• Polymorphic form and solid-state stability.
• Blend uniformity at high drug loading.
• Lubrication sensitivity.
• Coating weight gain and endpoint control.
• Moisture uptake.
• Dissolution after accelerated and long-term storage.
• Scale-up from laboratory granulation to commercial equipment.

Geographic opportunities are strongest in markets with growing self-medication, expanded generic access, or limited availability of pediatric NSAID dosage forms. Regulatory requirements differ across the United States, European Union, Japan, and emerging markets. A global excipient strategy should account for regional excipient monographs, permitted colorants, nitrosamine and elemental-impurity controls, local labeling requirements, and bioequivalence standards.

What licensing and partnership opportunities exist for Naprosyn excipients?

Licensing value is more likely to sit with the formulation platform than with naproxen itself. Relevant partners include:

• Excipient manufacturers with novel co-processed or functional excipients.
• Drug-delivery companies with taste-masking, enteric, or controlled-release technology.
• Contract development and manufacturing organizations with high-containment or coating capacity.
• Consumer-health companies with OTC distribution.
• Specialty pharmaceutical companies developing pediatric or gastroprotective products.

A strong deal structure would define ownership of formulation patents, improvements, process know-how, regulatory data, territory, supply rights, minimum purchase commitments, and exclusivity. Excipient suppliers may seek preferred-supplier status or rights to approve substitutions. The sponsor should preserve substitution rights where regulatory comparability permits.

Key Takeaways

• Naprosyn’s basic active ingredient and immediate-release tablet have no meaningful new-product exclusivity.
• Generic competition makes a conventional naproxen tablet a weak commercial target.
• The best excipient opportunities are pediatric liquids, dispersible products, rapid-onset naproxen sodium, smaller tablets, and selected gastroprotective combinations.
• Enteric coating can change release location but does not eliminate systemic NSAID risks.
• New patent value should come from measurable formulation or manufacturing performance, not routine excipient aggregation.
• A 505(b)(2) strategy may provide a practical route for differentiated dosage forms, while ANDA products face direct generic price competition.
• The FDA Orange Book and current FDA labeling should control any product-specific conclusion on listed patents, inactive ingredients, and exclusivity.[1,2]

FAQs

Can a new excipient create exclusivity for Naprosyn?

An excipient alone normally does not create exclusivity. Protection may arise from a novel composition, manufacturing process, or clinical-use claim that incorporates the excipient and produces a patentable technical result.

Is naproxen sodium better than naproxen for rapid-release products?

Naproxen sodium generally dissolves faster because it is more water-soluble. The final product still depends on particle size, granulation, disintegration, buffering, and moisture control.

Can an enteric-coated Naprosyn product claim reduced gastrointestinal risk?

Not automatically. Enteric coating may reduce gastric exposure to undissolved drug, but systemic NSAID toxicity remains. A reduced-risk claim would require appropriate clinical evidence and regulatory review.

What is the strongest pediatric formulation opportunity for naproxen?

A palatable, stable liquid or dispersible granule with accurate dosing has the clearest opportunity. Taste masking, sedimentation control, dose flexibility, and microbiological stability are the critical development variables.

Are Naprosyn excipient patents likely to block generic naproxen?

Legacy excipient patents are unlikely to block ordinary generic naproxen tablets. A new formulation patent could affect a specific delayed-release, liquid, rapid-release, or combination product if the patent is valid, enforceable, and properly listed.

References

1. U.S. Food and Drug Administration. (n.d.). Naprosyn: Prescribing information and inactive ingredients. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

4. U.S. Food and Drug Administration. (2024). Approved drug product list and patent and exclusivity information. FDA.

5. U.S. Food and Drug Administration. (2019). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA Guidance for Industry.